Spots Global Cancer Trial Database for Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Official Title: Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma
Study ID: NCT01590472
Conditions
Interventions
Study Description
Brief Summary: The purpose of this research study is to investigate the possibility that a person's genes put a person at a higher risk of developing mesothelioma. The investigators will examine genes from DNA (genetic material) isolated from blood. This study will also examine the impact of environmental and work exposures and family history of common cancers on the development of mesothelioma. The genetic markers in this study will basically identify how a person's body processes frequently encountered environmental pollutants and will not tell about chromosomes, specific diseases, or other potential health problems.
Detailed Description: Mesothelioma is a cancer that develops from serosal surfaces usually in response to prior asbestos exposure. A history of asbestos exposure can be elicited in more than 80% of mesothelioma victims. However, asbestos exposure alone is not sufficient to cause the development of mesothelioma. Nearly 27 million individuals in the US, were exposed to asbestos in the work place between 1940 and 1979 but just 3,000 new cases of mesothelioma are diagnosed each year. Therefore, the investigators hypothesis is that genetic variation in addition to asbestos exposure, and host factors contribute to the development of mesothelioma. It is estimated, based on the investigators preliminary studies, that a population in excess of 1,000 subjects with mesothelioma is required to perform a valid GWAS. Therefore a multicenter approach is necessary to collect data and DNA on sufficient numbers with mesothelioma to adequately evaluate genetic risk. It is the aim of this proposal to develop a consortium of mesothelioma investigators to share phenotypic data and DNA samples and to perform genome wide association scanning (GWAS).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Johns Hopkins University, Baltimore, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
New York University School of Medicine, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Jill Ohar, MD
Affiliation: Wake Forest University
Role: STUDY_DIRECTOR
Name: Lee Krug, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Julie Brahmer, MD
Affiliation: Johns Hopkins University
Role: PRINCIPAL_INVESTIGATOR
Name: Harvey I Pass, MD
Affiliation: NYU Langone Health
Role: PRINCIPAL_INVESTIGATOR
Name: Tobias Peikert, MD
Affiliation: Mayo Clinic
Role: PRINCIPAL_INVESTIGATOR
Name: Daniel H Sterman, MD
Affiliation: University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
